Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs Chemotherapy in First-Line Advanced Triple-Negative Breast Cancer
NCT06279364Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Feb 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Kelun-Biotech. Started Feb 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06279364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279364.